BTS Appointed Exclusive Global A2P SMS Aggregator for BBIX and SoftBank Corp.
20.1.2025 07:00:00 CET | Business Wire | Press release
Business Telecommunications Services, Inc. (BTS), a leading provider, technology enabler, and trusted partner to CommTech players, has today announced its appointment as the exclusive international A2P SMS aggregator for BBIX, Inc. (BBIX), a wholly-owned subsidiary and the official international A2P SMS gateway of SoftBank Corp. (SoftBank). This agreement marks a significant milestone in the five-year partnership between BTS, BBIX, and SoftBank, enabling seamless and innovative international communication solutions.
As the exclusive aggregator, BTS will be the official channel for terminating international A2P SMS traffic to the SoftBank network. This partnership mandates all communications providers to route their traffic destined for SoftBank through BTS, ensuring seamless and secure delivery. By leveraging the complementary strengths of each company, this partnership enhances the global messaging ecosystem with improved operational efficiencies, enabling a better customer experience and more responsive customer support.
BTS's extensive global footprint and BBIX's market expertise will help partners navigate complex regulatory environments, expand market reach, and unlock cross-selling opportunities that can drive higher revenue growth. The partnership also ensures the delivery of secure and reliable messaging services by leveraging BTS’s advanced S1 Platform.
“As a trusted partner, we are pleased to expand our collaboration with BTS to ensure the seamless aggregation of global A2P SMS traffic,” said Hideyuki Sasaki, President & CEO of BBIX. “By combining our strengths and complementary expertise, we are delivering a secure and reliable solution that enhances the SoftBank network and supports the evolving needs of our global partners.”
“As a trusted partner and joint venture collaborator, BTS has consistently demonstrated the capabilities and expertise we need to support SoftBank’s global communications strategy,” commented Norioki Sekiguchi, Vice President of SoftBank Corp.’s Global Business Division. “By leveraging BBIX as our official gateway, BTS will ensure the seamless and secure aggregation of international A2P SMS traffic to our network, enabling us to deliver greater reliability and performance for our customers worldwide.”
This agreement solidifies BTS’s leadership in the global messaging space and underscores the ongoing collaboration between BTS, BBIX, and SoftBank. Together, they continue to pioneer innovative and scalable solutions that address the dynamic needs of the global communications industry.
“Becoming the exclusive aggregator of A2P SMS for BBIX and SoftBank marks an important milestone in our partnership, which began over five years ago,” concluded Andrés Proaño, EVP & CRO of BTS. “This collaboration reflects the strength of our relationship and our shared commitment to driving innovation in global communications. With many more strategic initiatives ahead, such as Open Connectivity eXchange (OCX), Roaming Peering eXchange (RPX), and advanced AI solutions, this agreement is a key step forward in a partnership poised for even greater growth and success.”
About BTS
BTS is a leading global provider, technology enabler, and trusted partner to CommTech players. Leveraging its proprietary S1 Platform and an international network of 400+ direct partners, BTS delivers advanced AI-driven solutions specializing in voice, messaging, cloud communications, and innovative services that drive growth for MNOs, carriers, digital players, and hyperscalers. BTS powers 18+ billion voice minutes annually across 180+ countries, with extensive cloud telephony coverage in 90+ hard-to-reach markets and global reach for messaging services.
About BBIX
BBIX was established in 2003 to be a carrier-free internet exchange (IX) provider headquartered in Japan and serving Asia, Europe, and the US. It provides various connectivity services such as IX, Roaming Peering eXchange (RPX), Open Connectivity eXchange (OCX), as well as A2P SMS solutions. BBIX has established itself as one of the leading IXs in Asia, with a growing membership and an expanding global footprint.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250119536400/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom